## Pharmacy Prior Authorization

## AETNA BETTER HEALTH ILLINOIS FAMILY HEALTH PLAN (MEDICAID)

Oncology Antineoplastic Agents (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at **1-844-242-0908**.

When conditions are met, we will authorize the coverage of Oncology Antineoplastic Agents (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name			
Please specify			
Quantity	Frequency	Strength	
Route of Administration	Expected Length of therapy		
Patient Information			
Patient Name:			
Patient ID:			
Patient Group No :			
Patient DOB:			
Patient Phone:			
Prescribing Physician			
Physician Name:			
Specialty:	NPI Number:		
Physician Fax:	Physician Phone:		
Physician Address:	City, State, Zip:		
Diagnosis:	ICD Code:		
Please circle the appropriate answ	er for each question.		
	this medication in the past for this patient ion is on file under this plan)?	Y	N
<ol><li>Has the patient had clini stabilization of the disea [If no, then no further qu</li></ol>		Y	N
3. Is adverse effect monitor FDA-approved label? [If no, then no further qu	ring being done as recommended in the estions]	Y	N
	ation being adjusted as needed for nthe FDA-approved level?	Υ	N

Reference Number: C9862-A / Effective Date: 02/01/2017

[No further questions.]

5.	Is the medication being prescribed for an FDA-approved indication? [If yes, skip to question 7]	Υ	N
6.	Is the medication being prescribed for a "medically accepted indication" as noted in any of the following Compendia? A) NCCN Drugs and Biologic Compendium or NCCN Clinical Practice Guidelines, category 1, 2a, or 2b, B) Micromedex DrugDex, or C) Clinical Pharmacology.  [If no, then no further questions]	Y	N
7.	Is the patient under the care of an oncologist? [If no, then no further questions]	Y	N
8.	Have medical records, lab results, test results, and clinical markers supporting the diagnosis and treatment been submitted with the request? [If no, then no further questions]	Y	N
9.	Does the patient have any contraindications to the requested medication OR is the patient taking other medications that should be avoided with the requested drug based on the FDA-approved labeling? [If yes, then no further questions]	Y	N
10	Is the request for experimental/investigational use or for a patient enrolled in a clinical trial for the condition being treated by the requested drug?  [If yes, then no further questions]	Y	N
11	Does the prescribed dose fall within the FDA-approved range for the indication and patient specific factors (e.g., age, weight or BSA, renal function, liver function, drug interactions, etc)? [If no, then no further questions]	Y	N
12	Is the requested medication a formulary preferred product? [If yes, then no further questions]	Y	N
13	.Were trials of formulary preferred agents for an adequate duration not effective or poorly tolerated? [If yes, then no further questions]	Υ	N
14	Are all other formulary preferred alternatives contraindicated based on the patient's other medical conditions or drug interactions? [If yes, then no further questions]	Y	N
15	. Is the request for treatment of an indication for which there are no	Υ	Ν

Reference Number: C9862-A / Effective Date: 02/01/2017

Prescriber (Or Authorized) Signature	Date		
I affirm that the information given on this form is true and accurate as of this date	<del>)</del> .		
Comments:			
16. Does the patient have a genetic mutation that is resistant to the formulary preferred agents?	Υ	N	
formulary preferred medications? [If yes, then no further questions]			

Reference Number: C9862-A / Effective Date: 02/01/2017